Close
Help




JOURNAL

Clinical Medicine Insights: Therapeutics

1,371,792 Journal Article Views | Journal Analytics

Sitaxentan for the Oral Treatment of Pulmonary Arterial Hypertension: Benefits from Endothelin Receptor Subtype Selectivity?

Submit a Paper



Publication Date: 16 Apr 2009

Type: Review

Journal: Clinical Medicine Insights: Therapeutics

Citation: Clinical Medicine: Therapeutics 2009:1 111-121

Hermann A.M. Mucke

H.M. Pharma Consultancy, Wien (Vienna), Austria.

Abstract

Pulmonary arterial hypertension (PAH) is a deadly and underdiagnosed disease which causes right heart failure secondary to pressure overload resulting from the thickening of the pulmonary artery endothelium, associated with elevated levels of circulating endothelin-1. Sitaxentan was the first endothelin antagonist with high selectivity for receptor subtype A (over subtype ET-B) to gain regulatory approval for the treatment of PAH in major pharmaceutical markets. This review traces the development history of sitaxentan, summarizes the designs and results from its clinical studies, and relates the drug’s profile to that of the two other broadly available endothelin receptor antagonists, bosentan and ambrisentan. All three drugs have comparable therapeutic efficacy in the 6-minute walk test—a frequently employed standard—during the first 3–4 months of therapy. Their performance might differ slightly in other clinically relevant outcome measures, especially in longer-term treatment where fully comparable data have not yet been reported. In clinical trials of up to one year duration the propensity of sitaxentan to induce elevation of liver transaminases and hepatic failure was significantly lower than that of bosentan. As a once-daily oral drug with good tolerability sitaxentan has become a crucial element in the treatment of PAH.


Downloads

RIS citation   (ENDNOTE, REFERENCE MANAGER, PROCITE, REFWORKS)

BibTex citation   (BIBDESK, LATEX)






What Your Colleagues Say About Clinical Medicine Insights: Therapeutics
testimonial_image
Every step of publishing with Clinical Medicine Insights: Therapeutics was a smooth and positive experience.  What impressed me the most was the proficiency and rigor of the reviewers, whose feedback greatly enriched the final article.  I definitely enjoyed the process.
Dr Viviana Ritacco (Consejo Nacional de Investigaciones Científicas y Técnicas and Instituto Nacional de Enfermedades Infecciosas ANLIS “Carlos G. Malbrán”, Buenos Aires, Argentina)
More Testimonials

Quick Links


Follow Us We make it easy to find new research papers.